Kevin K Gordon's most recent trade in Progyny Inc was a trade of 34,049 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Progyny Inc | Kevin K. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 34,049 | 34,049 | - | - | Stock Option (Right to Buy) | |
| Progyny Inc | Kevin K. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 8,026 | 13,173 (0%) | 0% | 0 | Common Stock | |
| Progyny Inc | Kevin K. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 6,600 | 6,600 | - | - | Stock Option (Right to Buy) | |
| Progyny Inc | Kevin K. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 23,212 | 23,212 | - | - | Stock Option (Right to Buy) | |
| Progyny Inc | Kevin K. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 5,147 | 8,801 (0%) | 0% | 0 | Common Stock | |
| Progyny Inc | Kevin Gordon K. | Director | Sale of securities on an exchange or to another person at price $ 35.93 per share. | 11 Dec 2023 | 2,500 | 9,854 (0%) | 0% | 35.9 | 89,825 | Common Stock |
| Progyny Inc | Kevin K. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 16,990 | 16,990 | - | - | Stock Option (Right to Buy) | |
| Progyny Inc | Kevin K. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 3,654 | 13,764 (0%) | 0% | 0 | Common Stock | |
| Progyny Inc | Kevin K. Gordon | Director | Sale of securities on an exchange or to another person at price $ 38.24 per share. | 24 May 2023 | 1,410 | 12,354 (0%) | 0% | 38.2 | 53,918 | Common Stock |
| Progyny Inc | Kevin K. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2022 | 14,500 | 14,500 | - | - | Stock Option (Right to Buy) | |
| Progyny Inc | Kevin K. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2022 | 2,900 | 10,110 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Kevin K. Gordon | Director | Sale of securities on an exchange or to another person at price $ 18.50 per share. | 08 Jun 2022 | 15,000 | 8,720 (0%) | 0% | 18.5 | 277,502 | Common Stock |
| Veracyte Inc | Kevin K. Gordon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2022 | 15,000 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Kevin K. Gordon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.39 per share. | 08 Jun 2022 | 15,000 | 23,720 (0%) | 0% | 7.4 | 110,850 | Common Stock |
| Progyny Inc | Kevin K. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2021 | 14,658 | 14,658 | - | - | Stock Option (right to buy) | |
| Progyny Inc | Kevin K. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2021 | 2,210 | 7,210 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Kevin K. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 8,720 | 8,720 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Kevin K. Gordon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 10,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Kevin K. Gordon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.39 per share. | 04 Jan 2021 | 10,000 | 10,000 (0%) | 0% | 7.4 | 73,900 | Common Stock |
| Veracyte Inc | Kevin K. Gordon | Director | Sale of securities on an exchange or to another person at price $ 49.27 per share. | 04 Jan 2021 | 5,523 | 0 (0%) | 0% | 49.3 | 272,134 | Common Stock |
| Veracyte Inc | Kevin K. Gordon | Director | Sale of securities on an exchange or to another person at price $ 48.62 per share. | 04 Jan 2021 | 4,477 | 5,523 (0%) | 0% | 48.6 | 217,664 | Common Stock |
| Veracyte Inc | Kevin K. Gordon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2020 | 10,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Kevin K. Gordon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.39 per share. | 12 Nov 2020 | 10,000 | 10,000 (0%) | 0% | 7.4 | 73,900 | Common Stock |
| Veracyte Inc | Kevin K. Gordon | Director | Sale of securities on an exchange or to another person at price $ 46.95 per share. | 12 Nov 2020 | 8,194 | 1,806 (0%) | 0% | 47.0 | 384,722 | Common Stock |
| Veracyte Inc | Kevin K. Gordon | Director | Sale of securities on an exchange or to another person at price $ 47.85 per share. | 12 Nov 2020 | 1,806 | 0 (0%) | 0% | 47.8 | 86,415 | Common Stock |
| Progyny Inc | Kevin K. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2020 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Progyny Inc | Kevin K. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2020 | 5,000 | 5,000 (0%) | 0% | 0 | Common Stock |